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In their letter to the editor, Vita and De Peri question whether new meta-analyses and mega-
analyses of magnetic resonance imaging (MRI) findings in schizophrenia increase our 
knowledge about the nature of the disease process. In general, meta-analyses and mega-analyses 
provide objective methods to critically summarize a body of evidence regarding a particular 
question. As there had been no coordinated meta-analysis of cortical thickness and surface area 
abnormalities in schizophrenia, it is our view that this new, collaboratively conducted meta-
analysis (1) contributes to our knowledge on this question and offers information on the cross-
site consistency of observed disease effects. Regional effects on cortical thickness and surface 
area can be difficult to summarize based on the traditional, literature-based, meta-analysis 
method, given the heterogeneity of analysis methods used in individual studies. 
The Enhancing Neuro Imaging Genetics through Meta Analysis (ENIGMA) approach of 
collaboratively conducting meta-analyses -in contrast to the traditional literature-based meta-
analysis- offers additional benefits. First, ENIGMA’s publicly available methods lend 
themselves well to independent replication of imaging findings (2, 3), which is crucial given the 
‘crisis of replication’ in neuroscience (4–6). Second, use of the same quality assurance, image 
processing, and statistical analysis methods across samples within and across ENIGMA working 
groups, minimizes method-related heterogeneity and offers the potential for straightforward 
cross-disorder comparisons (7–11). Third, use of similar meta-analytic methods across 
worldwide samples has generated imaging and genetics findings with sample sizes beyond the 
scope of any individual laboratory or consortium studying a single disorder (12–15).  
Vita and De Peri repeat one of the study weaknesses already listed in the discussion, namely that 
possible group differences in lateralization were not examined. This question is under 
investigation by the ENIGMA Laterality Working Group, which is currently examining healthy 
and disordered brain laterality (16, 17). ENIGMA coordinates publication efforts across working 
groups in order to avoid overlap. Moreover, numerous ENIGMA studies make important 
contributions showing between-disorder brain differences without addressing laterality. 
Vita and De Peri also mention that the meta-analysis does not address possible differential 
longitudinal trajectories between individuals with schizophrenia and healthy volunteers, which is 
also correct as this cross-sectional meta-analysis did not aim to examine longitudinal trajectories. 
There are ongoing efforts by the ENIGMA Plasticity Working Group to study genetic influences 
on individual differences in longitudinal brain changes (18). We agree that further investigation 
of questions regarding longitudinal trajectories of brain changes across the lifespan, especially 
prior to illness onset, e.g., in adolescents at clinical high risk for psychosis, as well as after a first 
psychotic episode, will provide valuable information with regard to schizophrenia pathogenesis 
and several such analyses are planned or already ongoing. 
Vita and De Peri further state that the meta-analysis does not add relevant information about the 
effects of antipsychotic medication on brain morphology but qualify that the reported findings 
seem compatible with findings from longitudinal MRI studies that suggest different effects of 
first versus second-generation antipsychotic treatments on cortical gray matter changes. We point 
out that prior meta-analyses did not dissociate effects of antipsychotic treatments on cortical 
surface area versus cortical thickness, whose product constitutes gray matter volume, and that the 
consistency of findings is important in the light of reports on non-replication in neuroscience. 
The comment that “the supposed huge statistical power of mega-analyses of MRI findings in 
schizophrenia may be undermined by the large variation of data obtained by different centers in 
disparate conditions” is incorrect. First, Van Erp et al. (2018) is a meta-analysis and not a mega-
analysis, which like any other meta-analysis, summarizes within-sample effects. In fact, joint 
meta-analyses tend to reduce method-related variation when compared to literature-based meta-
analyses because similar analysis methods are applied across samples. Second, multiple imaging 
genetics meta-analyses replicate common genetic variants associated with measures of brain 
structure and find a greater number of common variants associated with these measures when 
additional independent samples are added (19–21). These findings suggest increased power as 
brain imaging data from independent samples are added. Finally, the suggestion that mega-
analyses of MRI data are undermined by between site variation is not borne out by the facts. 
Research from a decade ago showed the feasibility and the additional power gained by pooling 
legacy structural imaging data (22). More recent studies show that meta-analyses and mega-
analyses of structural imaging data, whether from prospective multi-scanner or independent 
samples, yield significant and very similar findings (23–25). Each analysis method has strengths, 
weaknesses, and pitfalls. Hence researchers must consider whether to conduct a meta-analysis, a 
mega-analysis, or both, to answer a particular question. The suggestion that meta-analyses and 
mega-analyses are not hypothesis-driven approaches is also incorrect. All of the published 
ENIGMA Schizophrenia Working Group meta-analyses to date list their hypotheses at the end of 
their introductions (1, 2, 26–28). Of note, nowhere in the manuscript do we state that “meta-
analyses provide better evidence than large, well designed, hypothesis-driven, high-quality 
individual trials”. On the contrary, all findings from meta-analyses depend on the quality of the 
studies on which they are based. Even so, meta-analyses can offer additional safeguards against 
false positive findings generated by individual studies with small or highly heterogeneous 
samples by taking into account each sample’s error terms. We do agree that missing data for 
known or supposed significant moderators can be an issue. However, this is a criticism of all 
analyses of scientific data, rather than of our study specifically. 
Finally, we respectfully disagree with the statement by Vita and De Peri “that the time has come 
for applying really new approaches to the study of the nature of the disease process underlying 
schizophrenia, rather than promoting redundant research on mega-databases which may even 
dilute or confuse established knowledge”. We believe there is value both in the relatively new 
approach of large-scale collaborative research on costly, already collected data, as well as 
applying other innovative approaches and experimentation in adequately powered samples. We 
believe that most scientists who contribute to ENIGMA or other consortia as well as the funding 
agencies who promote large-scale data sharing and analysis recognize that both approaches make 
valuable contributions to the field. 
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